Vericel Corp (VCEL)
Health Care / Biotechnology
S&P SmallCap 600$32.58
Below average on several measures. Research carefully.
Weak
Score based on 3 of 5 models — moderate confidence
Is Vericel Corp a Good Investment in 2026?
Vericel Corp (VCEL) scores 4.3 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Piotroski model rates Vericel Corp as Strong (7/9). However, the Graham model rates it Caution — Significantly above fair value. Vericel Corp ranks #783 out of 1127 stocks in the Health Care sector.
This summary is algorithmically generated and is not financial advice.
Key Metrics
Valuation
Trades at 103x earnings — significantly above sector median of 25x. Premium reflects market growth expectations.
Fair value estimate not available for this stock.
5-Model Analysis
Each model evaluates this stock from a different angle. Combined, they form the composite score above.
Piotroski
Strong
7/9
Buffett
Neutral
Business quality & competitive moat
Graham
Caution
Significantly above fair value
Lynch
Limited Data
Growth rate vs price (PEG)
Greenblatt
Limited Data
Earnings yield + return on capital
Frequently Asked Questions
Is Vericel Corp (VCEL) a good investment?
What is Vericel Corp's Piotroski F-Score?
Is VCEL overvalued or undervalued?
How does VCEL compare to other Health Care stocks?
What do investment models say about VCEL?
Similar Stocks
Compare VCEL with
Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer